Plasma Thrombin-Activatable Fibrinolysis Inhibitor Levels Are not Associated With Glucose Intolerance and Subclinical Atherosclerosis in Women With Previous Gestational Diabetes

Clinical and Applied Thrombosis/Hemostasis - Tập 17 Số 6 - Trang E224-E230 - 2011
Barış Akıncı1,2, Aygül Çeltik3, Serkan Yener1, Sinan Genç4, Sunay Tunalı5, Faize Yüksel5, Mehmet Ali Özcan5, Mustafa Seçil4, Sena Yeşil1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey
2Izmir Tepecik Research and Training Hospital, Izmir, Turkey
3Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey
4Department of Radiology, Dokuz Eylul University, Izmir, Turkey
5Division of Hematology, Department of Internal Medicine, Dokuz Eylul University, Izmir, Turkey

Tóm tắt

We aimed to determine plasma thrombin-activatable fibrinolysis inhibitor (TAFI) antigen levels in women with previous gestational diabetes mellitus (GDM) and to evaluate the possible association of plasma TAFI with glucose intolerance and markers of subclinical atherosclerosis. This cross-sectional study was performed in 111 women with previous GDM and 60 controls. Glucose intolerance was evaluated. Homeostasis model assessment score was calculated. Circulating lipids, interleukin-6, matrix metalloproteinase-1, fibrinogen, plasminogen activator inhibitor-1, and TAFI antigen levels were assayed. Carotid intima media thickness (IMT) was measured. Women with previous GDM had increased levels of atherosclerosis markers and carotid IMT. On the other hand, plasma TAFI antigen levels were similar ( P = .395). Thrombin-activatable fibrinolysis inhibitor was not associated with the indices of insulin resistance, glucose intolerance, markers of atherosclerosis, and carotid IMT. Our data demonstrated that plasma TAFI was not altered in women with previous GDM. TAFI was not associated with glucose intolerance and subclinical atherosclerosis.

Từ khóa


Tài liệu tham khảo

10.1016/S0049-3848(09)70143-4

10.1111/j.1538-7836.2005.01420.x

10.1007/s11892-006-0052-5

10.1016/j.fertnstert.2008.12.007

10.1055/s-0029-1225260

10.1016/j.atherosclerosis.2006.09.017

10.1016/j.diabres.2008.07.014

10.1002/uog.2687

10.1016/j.diabres.2007.04.013

10.1111/j.1365-2362.2006.01630.x

10.1080/07853890600852898

Morser J, 2010, J Thromb Haemost, 8, 868, 10.1111/j.1538-7836.2010.03787.x

10.1210/jcem.87.2.8214

10.1210/jc.2002-020691

10.1160/TH09-10-0682

10.1097/00001721-200309000-00006

10.1160/TH09-01-0016

10.1016/j.diabres.2008.03.003

2010, Diabetes Care, 33, S62

10.1093/clinchem/18.6.499

10.1159/000205234

10.2337/dc09-S330

10.1161/01.ATV.20.9.2156

10.1182/blood.V97.7.2053

10.1016/j.jdiacomp.2005.05.003

10.1016/j.metabol.2005.11.010

Silveira A, 2000, Thromb Haemost, 84, 364

10.1055/s-0037-1613349

10.1161/01.STR.0000063139.06585.45

10.1111/j.1538-7836.2005.01486.x

10.1046/j.1538-7836.2003.00398.x

10.1111/j.1538-7836.2008.03221.x

10.1160/TH06-06-0295

10.1046/j.1538-7836.2003.00147.x

10.1055/s-2007-992118

10.1159/000215722

10.1111/j.1464-5491.2007.02204.x

Thông tin
Thông tin xuất bản

Clinical and Applied Thrombosis/Hemostasis

Tập 17 Số 6

E224-E230

Thông tin tác giả